Document text
Principal Investigator: Catarina E Hioe
Organization: JAMES J PETERS VA MEDICAL CENTER
Fiscal Year: 2022
Funding agency: Veterans Affairs
Project Summary/Abstract
The COVID-19 pandemic, which is caused by SARS-CoV-2, a novel coronavirus first detected in
November-December 2019, has inflicted millions of deaths worldwide. In the US, the outbreak is affecting
millions of lives. The VA hospitals, including the James J. Peters VA Medical Center (JJP VAMC) in the Bronx,
NY, have responded promptly to provide care to Veterans and employees. Veterans are typically older than the
general US population, making them highly susceptible to severe disease. COVID-19 vaccines are also
distributed initially to the elderly and other high-risk individuals. This provides the VA a unique opportunity to
study SARS-CoV-2 infection and vaccination in the most vulnerable individuals.
This VA Merit application proposes to investigate the protective role of antibodies (Abs) elicited against
the SARS-CoV-2 spike protein and its receptor-binding domain (RBD) following vaccination or infection. In
particular, we will examine the Ab Fc properties and functions that are not well understood and the Abs that are
present in blood and in saliva as a proxy of Abs at the mucosal site of virus entry. The proposed study is built
upon our published and preliminary results showing the detection of different immunoglobulin (Ig) isotypes
against SARS-CoV-2 spike and RBD in saliva vs plasma of convalescent COVID-19 patients and vaccine
recipients. Interestingly, our preliminary data indicate a lack of correlation of spike-specific Ig isotypes in saliva
vs plasma from infected and vaccinated subjects. The data further show the binding of C1q, the first
component in the classical complement cascade, to Abs from both infected and vaccinated subjects. Notably,
the C1q binding activities of Abs in saliva vs plasma correlated poorly, offering the initial evidence for
differential Fc functions of mucosal vs circulating anti-spike Abs elicited by infection and vaccination.
To investigate further the Fc properties and functions of Abs against SARS-CoV-2, we hypothesize
that Fc isotype and glycosylation are the key determinants of Fc-dependent Ab functions in protection
against COVID-19. A research team that include research specialists with expertise in Abs and viral
immunology (PI: Catarina Hioe at JJP VAMC; collaborators: Susan Zolla-Pazner, Chitra Upadhyay, Ray
Alvarez at Mount Sinai School of Medicine/MSSM), an expert in mass spectrometry and glycan biology (Hui
Zhang at Johns Hopkins Univ), and an infectious disease clinician (Co-I: Juan Bandres at JJP VAMC) will work
together to test this hypothesis. We will leverage our extensive expertise in Abs against HIV envelope
glycoprotein and our experience investigating Ab responses against SARS-CoV-2 in the past year. In Aim 1,
we will collect longitudinal plasma and saliva samples to determine the isotypes and durability of Abs against
spike and RBD in different bodily fluids of ambulatory and hospitalized COVID-19 patients and healthy
uninfected recipients of COVID-19 RNA vaccines. Aim 2 will evaluate the glycan structures on the Fc regions
of Abs against spike from SARS-CoV-2-infected and vaccinated subjects. Aim 3 will assess the Fc-mediated
activities that these Abs mediate to destroy virus particles and virus-infected cells, i.e. complement
binding/activation and FcɣR-mediated signaling, cytotoxicity, and phagocytosis. Abs of different Ig isotypes and
with experimentally modified Fc glycans will also be examined for their Fc-dependent activities. The proposed
study will produce data critical to advance the development of improved Ab-based arsenals for diagnostics,
prophylactics, and therapeutics against COVID-19.
Terms: <19S Gamma Globulin><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><7S Gamma Globulin><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Advanced Development><Affect><Affinity><Animals><Antibodies><Antibody Response><Antigens><Binding><Biology><Blood><Blood Neutrophil><Blood Plasma><Blood Polymorphonuclear Neutrophil><Blood Reticuloendothelial System><C1 q><C1q><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 crisis><COVID-19 diagnostic><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 intervention><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 diagnostic><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 intervention><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 vaccine><COVID19 virus><CV-19><CV19><Caring><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cessation of life><China><Chitra><CoV emergence><CoV-2><CoV2><Communicable Diseases><Complement><Complement 1q><Complement C1q><Complement Proteins><Coronavirus Disease 2019 intervention><DNA Vaccines><Data><Death><Death Records><Deposit><Deposition><Detection><Development><Diagnostic><Disease><Disease Outbreaks><Disease Outcome><Disorder><Elderly><Emergencies><Emergency Situation><Employee><Failure><Glycans><Glycoproteins><Goals><HIV><Hospitals><Human><Human Immunodeficiency Viruses><IgA><IgG><IgG1><IgM><Immunoglobulin A><Immunoglobulin G><Immunoglobulin Isotypes><Immunoglobulin M><Immunology><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Inflammatory><Intracellular Communication and Signaling><LAV-HTLV-III><Lead><Liquid substance><Lymphadenopathy-Associated Virus><Lytotoxicity><M mulatta><M. mulatta><Macaca mulatta><Mainland China><Marrow Neutrophil><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Mediating><Medical center><Metabolic Glycosylation><Modern Man><Molecular Interaction><Mucosa><Mucosal Tissue><Mucous Membrane><Myeloid Cells><Naked DNA Vaccines><Neutrophilic Granulocyte><Neutrophilic Leukocyte><Outbreaks><Patients><Pb element><Phagocytosis><Plasma><Plasma Serum><Polymorphonuclear Cell><Polymorphonuclear Leukocytes><Polymorphonuclear Neutrophils><Polysaccharides><Population><Position><Positioning Attribute><Production><Property><Proxy><Publishing><RNA vaccine><RNA-based vaccine><Recombinant DNA Vaccines><Reporting><Research><Research Specimen><Reticuloendothelial System, Serum, Plasma><Rhesus Macaque><Rhesus Monkey><Risk Factors><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 diagnostic><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Saliva><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Specialist><Specimen><Structure><Symptoms><Testing><Time><Vaccination><Vaccinee><Vaccines><Veterans><Viral><Virion><Virus><Virus Particle><Virus-HIV><Vulnerable Populations><Work><Wuhan coronavirus><advanced age><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody-dependent cellular phagocytosis><base><biological signal transduction><convalescent plasma><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 diagnostic><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus patient><cytokine><cytotoxicity><developmental><elders><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experience><fluid><geriatric><glycosylation><hCoV19><heavy metal Pb><heavy metal lead><high risk><immunogen><improved><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><late life><later life><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><liquid><mRNA vaccine><mRNA-based vaccine><male><medical college><medical schools><mucosal site><nCoV><nCoV2><neutralizing antibody><neutrophil><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><older adult><older person><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pre-clinical study><preclinical study><prophylactic><receptor binding><receptor bound><response><saliva sample><salivary sample><school of medicine><senior citizen><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 diagnostic><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><vaccinated individual><vaccinated participant><vaccinated patient><vaccinated person><vaccinated subject><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vector><vulnerable group><vulnerable people>